Evidence map›Paper›PMID 42897128›Full record

ArticleSignal transduction and targeted therapy2026

Matrix metalloproteinase-guided targeting of vesicular stomatitis virus to tumors following systemic administration.

Eileen Victoria Theune, William C Theune, Elham Ahmadi, Conner C Chiari, Neha Singh, Rory Geyer, Jason Tonne, Muriel Metko, Olamide T Olaoba, Isabella China Wang and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Eileen Victoria TheuneDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
William C TheuneDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Elham AhmadiDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Conner C ChiariDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Neha SinghDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.ORCID http://orcid.org/0000-0001-9137-1103
Rory GeyerDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Jason TonneDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Muriel MetkoDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Olamide T OlaobaDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Isabella China WangDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Dylan DaiDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Jianbin RuanDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.ORCID http://orcid.org/0000-0001-5843-8273
Robert ClarkDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Guangfu LiDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Penghua WangDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.ORCID http://orcid.org/0000-0002-7332-1871
Evan R JellisonDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Anthony T VellaDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA.
Richard VileDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Kepeng WangDepartment of Immunology, University of Connecticut School of Medicine, UConn Health, Farmington, CT, USA. kewang@uchc.edu.

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Rory Smoot · 2018 to 2026
$20.5M
Skeletal, Craniofacial and Oral Biology Training GrantT90DE033006 · NIDCR · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI FRANK C NICHOLS · 2023 to 2026
$2.0M
Control of regulatory T cells by IL-17 in colorectal cancerR01CA262430 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI WANG, KEPENG · 2021 to 2025
$1.8M
ASCVD risk assessment in T2DM facilitated by novel computational immunology programsR01HL172239 · NHLBI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Anthony T Vella, Beiyan Zhou · 2024 to 2026
$1.6M
Characterizing the role of CSDE1 as a critical co-factor for VSV replication.R01AI170535 · NIAID · MAYO CLINIC ROCHESTER · PI Richard G. Vile · 2023 to 2026
$1.6M
How RNA binding proteins control effector T cell responsesR01CA282775 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Anthony T Vella · 2024 to 2026
$1.4M
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.R01CA269384 · NCI · MAYO CLINIC ROCHESTER · PI Richard G. Vile · 2023 to 2026
$1.4M
A novel "cap-linker" strategy to target oncolytic viruses to the tumorR01CA303989 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Kepeng Wang · 2026 to 2026
$500k
NCI NIH HHS P30 CA034196NCI NIH HHS P50 CA210964NCI NIH HHS R01 CA262430NCI NIH HHS R01 CA269384NCI NIH HHS R01 CA282775NCI NIH HHS R01 CA303989NHLBI NIH HHS R01 HL172239NIAID NIH HHS R01 AI170535NIDCR NIH HHS T90 DE033006U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA210964-06U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01AI170535U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA262430U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA269384U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA282775U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA303989U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL172239U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) T90DE033006
6 · The paper itself

Abstract

The lack of tumor-specific targeting by oncolytic viruses (OVs) restricts their therapeutic potential. Here, we report a "cap-linker" strategy to modify the vesicular stomatitis virus (VSV) glycoprotein (G protein, VSV-G

Indexed as

Interleukin-12Matrix MetalloproteinasesOncolytic VirotherapyVesiculovirusViral Envelope ProteinsAnimalsHumansMembrane GlycoproteinsMiceOncolytic VirusesTumor MicroenvironmentVesicular stomatitis Indiana virusG protein, vesicular stomatitis virusInterleukin-12Matrix MetalloproteinasesMembrane GlycoproteinsViral Envelope Proteins

Identifiers

PMID42897128
PMCPMC13680497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.